Metagenomi Therapeutics Price to Sales Ratio 2022-2025 | MGX
Historical PS ratio values for Metagenomi Therapeutics (MGX) over the last 10 years. The current P/S ratio for Metagenomi Therapeutics as of February 06, 2026 is .
| Metagenomi Therapeutics P/S Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Sales per Share | Price to Sales Ratio |
| 2026-02-09 | 1.53 | 1.77 | |
| 2025-09-30 | 2.37 | $0.86 | 2.74 |
| 2025-06-30 | 1.48 | $0.94 | 1.57 |
| 2025-03-31 | 1.36 | $1.26 | 1.08 |
| 2024-12-31 | 3.61 | $1.68 | 2.15 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.058B | $0.052B |
| Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $39.788B | 12.35 |
| BridgeBio Pharma (BBIO) | United States | $13.114B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.756B | 18.29 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.962B | 24.25 |
| Bausch Health Cos (BHC) | Canada | $2.181B | 1.55 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.345B | 9.69 |
| Taysha Gene Therapies (TSHA) | United States | $1.263B | 0.00 |
| Personalis (PSNL) | United States | $0.715B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.415B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.183B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |